Zumiez (NASDAQ:ZUMZ) Reports Q1 CY2026 In Line With Expectations But Stock Drops 10.7%

Zumiez (NASDAQ: ZUMZ) reported Q1 CY2026 revenue of $193.3 million, up 4.9% year over year and in line with Wall Street expectations. Next-quarter revenue guidance was $212.5 million, about 3.1% below analysts’ estimates. The company posted a GAAP loss of $0.82 per share, slightly better than consensus, and its shares fell 10.7% to $21.00.

Original reporting
Published Jun 4, 2026, 8:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 9:27 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Zumiez (NASDAQ:ZUMZ) Reports Q1 CY2026 In Line With Expectations But Stock Drops 10.7% — source image
Decision brief

The 30-second read

$ZUMZBearishMed
01

Why it matters

The key tradable datapoint is the next-quarter revenue guidance coming in below Wall Street estimates, which the market punished immediately despite an in-line Q1 revenue print.

02

Market read

Guidance shortfall is the dominant driver of near-term risk for ZUMZ, outweighing in-line Q1 revenue and modest margin/EBITDA outperformance.

03

What to watch

Same-store sales rose 4% YoY and management cited progress toward profitable growth; store closures can mechanically lift same-store metrics even while total revenue growth stays muted.

Relevance 9/10Novelty 8/10Timing: Post-earnings reaction day (stock down 10.7% immediately after results).

Background

Zumiez is a specialty street/skate apparel retailer; the article frames recent performance around store closures and same-store sales trends.

Company-level read

Ticker impact

$ZUMZBearishHigh confidence
Context

Zumiez reported Q1 CY2026 results in line, but guided next-quarter revenue below estimates, driving a -10.7% stock drop.

Expected impact

Bearish bias for the next few sessions as guidance miss can pressure estimates and sentiment.

Evidence & confidence

The article cites in-line Q1 revenue/EPS loss vs consensus, but highlights next-quarter revenue guidance $212.5M coming in 3.1% below estimates and notes the immediate -10.7% selloff.

Market effects

Signals continued pressure on discretionary specialty retail demand and/or merchandising execution, with guidance sensitivity outweighing in-line prints.

Primarily US retail sentiment; limited direct regional spillover implied.

Low—company-specific guidance miss without broader global macro linkage in the article.

Counterpoint

If gross margin and EBITDA beat were driven by cost discipline, the guidance miss may be temporary and could reverse if inventory/demand stabilizes.

Key entities

  • Zumiez

    Reported Q1 CY2026 results in line with expectations and issued next-quarter revenue guidance below analysts’ estimates.

Related articles

$SMCIMed

Super Micro Computer Landed $60 Billion in Orders Last Quarter, but Trades at Just $30

Super Micro Computer (SMCI) said it booked over $60B in new orders in its fiscal Q4 ended June 30, lifting backlog to a record. It guided FY2026 revenue near the low end of $11B to $12.5B and gross margins at 15% to 17%. The company also plans $7B equity financing for AI server orders, noting some orders may not be firm and citing an independent review tied to export control issues.

$CSCOMed

Cisco Stock Is Finally Pricing In A New Growth Story

Cisco raised full-year revenue and EPS guidance on May 13, 2026, citing AI infrastructure demand. Management expects about $9 billion in FY2026 AI orders from hyperscalers and cited 5 hyperscaler design wins in Q3. Cisco shares rose about 20% since, with product orders up 19% YoY excluding hyperscaler growth. Options imply 41% IV ahead of the next catalyst.

$RMDMed

Off Into Weekend, As Early Work Undone

ResMed (ASX:RMD) fell 8.29% on Friday and is 3.09% lower for the week after a strong run. The company reported a solid Q4, with FY26 revenue up 10% to $5.7b, gross Q4 margin 62.3%, FY EPS up 17% to $11.17, and a 10% dividend increase to $0.66. Morgan Stanley downgraded to Equal Weight and cut its price target, citing cooling growth and Philips’ potential US return in 2027.